Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | J. Cortes | P. Jain | F. Ravandi | Koichi Takahashi | G. Borthakur | E. Jabbour | N. Daver | W. Wierda | S. Pierce | K. Sasaki | M. Rios | Toshihisa Satta